Compugen achieves first milestone in Bayer collaboration

Compugen (CGEN) achieves the first preclinical milestone in the development of one of the two checkpoint protein candidates discovered by Compugen that are the basis for its collaboration with Bayer HealthCare (BAYRY) (BAYZF). The company is now eligible to receive a $1.2M milestone payment from Bayer.

The two firms formalized their partnership last August in a deal that could bring up to $530M to Compugen in milestone payments plus royalties on commercial sales of therapeutic antibodies developed by Bayer against the checkpoint proteins.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs